Our previous study showed that although greatest survival benefit was observed in patients with PD-L1–strong positive NSCLC, ICB therapy also significantly improved the survival of PD-L1–negative NSCLC (2). The gene discussed is CD274; the disease is non-small cell lung carcinoma.